Market revenue in 2023 | USD 11.3 million |
Market revenue in 2030 | USD 20.1 million |
Growth rate | 8.6% (CAGR from 2023 to 2030) |
Largest segment | Ferric carboxymaltose |
Fastest growing segment | Ferric Carboxymaltose |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Iron Dextran, Iron Sucrose, Ferric Carboxymaltose |
Key market players worldwide | AbbVie Inc, Civitas Resources Inc Ordinary Shares, Daiichi Sankyo Co Ltd, Sanofi SA, CSL Ltd, COSMOS Pharmaceutical Corp, Zydus Lifesciences, Rockwell Medical Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intravenous iron drugs market will help companies and investors design strategic landscapes.
Ferric carboxymaltose was the largest segment with a revenue share of 59.29% in 2023. Horizon Databook has segmented the Sweden intravenous iron drugs market based on iron dextran, iron sucrose, ferric carboxymaltose covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing rates of cancer, inflammatory bowel disease, and CKD have increased the demand for IV iron drugs to treat the resulting IDA, which is anticipated to drive market growth. In addition, strategic efforts undertaken by key players to increase access to IV iron drugs, as well as the approval and introduction of novel formulations, are anticipated to support market expansion.
According to Q-Med, Cosmofer, a low-molecular iron dextran product, was approved for the Swedish market. Regarding the sales rights for the medication in the Swedish market, it has a contract with the Danish producer Nebo/Pharmacosmos.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden intravenous iron drugs market , including forecasts for subscribers. This country databook contains high-level insights into Sweden intravenous iron drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account